CTRI/2013/09/003975已完成2 期
Efficacy and Safety of Propranolol on the Proliferative Phase of Infantile Hemangioma -
GCS Medical College and research centre0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Infants under 12 months
- •Presenting a hemangioma with the following characteristics:
- •osubcutaneous and / or cutaneous
- •oMinimum diameter of 1.5cm on face, 5cm outside face and 1cm if it is ulcerated.
- •owithout functional impairment requiring treatment or oral corticosteroid
- •Consent of both parents (or the person having parental authority in families)
排除标准
- •age: more than 12 months.
- •Indication of treatment with corticosteroids for an indication other than hemangioma
- •Indication of treatment with beta-blocker for another indication that the hemangioma
- •Infant presenting contra-indications for the administration of propranolol
研究者
相似试验
招募中
3 期
effect of Propranolol in Traumatic Brain Injury (TBI)IRCT20130310012776N4Shiraz University of Medical Sciences110
已完成
2 期
Oral propranolol and retinopathy of prematurityRetinopathy of prematurityIRCT20100512003915N21Tabriz University of Medical Sciences72
招募中
1 期
Evaluating the effect of oral Propranolol in preventing the progression of retinopathy of prematurityretinopathy of prematurity.Retinopathy of prematurity, unspecified, bilateralH35.103IRCT20230717058817N1Ardabil University of Medical Sciences66
进行中（未招募）
不适用
Safety and efficacy of treatment with propranolol in newborns suffering from rethinopathy of the preterm: a pilot study - Propranolol and ROPRetinopathy of the pretermMedDRA version: 9.1Level: HLGTClassification code 10047060EUCTR2010-018737-21-ITAZIENDA OSPEDALIERA MEYER
已完成
不适用
Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity (PROP-ROP)Retinopathy of prematurity (ROP), the leading cause of blindness in childrenNeonatal DiseasesOther retinal disordersISRCTN18523491A. Meyer University Children's Hospital (Italy)44